Deck 40: Hormone Replacement Therapy

ملء الشاشة (f)
exit full mode
سؤال
What is the duration of selective estrogen receptor modifier (SERM) use for menopausal issues?

A)It matches the five year duration for estrogen products.
B)The bone health impact allows long-term use.
C)The increased risk of breast cancer encourages tapering as soon as possible.
D)The abnormal lipid profile contributes to an early termination as soon as hot flashes no longer occur.
استخدم زر المسافة أو
up arrow
down arrow
لقلب البطاقة.
سؤال
Re-evaluation of the Women's Health Study has resulted in what changes in HRT implementation?

A)A combination of estrogen and progestin is no longer required in patients with an intact uterus.
B)Women with breast cancer survivorship over 10 years are no longer considered "at risk."
C)HRT can be used in the first five years of menopause without major risk increase.
D)Low-dose estrogen can be used again in women over 6
سؤال
Dosage changes of conjugated equine estrogen (Premarin) are made at _________ intervals.

A)1 to 2 week
B)2 to 4 week
C)6 to 8 week
D)12 week
سؤال
Women with an intact uterus should be treated with HRT with both estrogen and progestin due to:

A)Increased risk for endometrial cancer if estrogen alone is used
B)Combination therapy providing the best relief of menopausal vasomotor symptoms
C)Reduced risk for colon cancer with combined therapy
D)Lower risk of developing blood clots with combined therapy
سؤال
The optimal maximum time frame for HRT or estrogen replacement therapy (ERT) is:

A)Two years
B)Five years 3.10 years
C)15 years
سؤال
Kristine would like to start HRT to treat the significant vasomotor symptoms she is experiencing during menopause. Education for a woman considering HRT includes:

A)Explaining that HRT is totally safe if used short term
B)Telling her to ignore media hype regarding HRT
C)Discussing the advantages and risks of HRT
D)Encouraging her to use phytoestrogens with HRT
سؤال
Which of the following is not an indication for starting HRT?

A)Symptomatic hot flashes
B)Treatment or prevention of vaginal atrophy
C)Prevention of osteoporosis
D)Early surgical menopause
سؤال
All of the following are risks of exogenous hormones except:

A)Breast cancer
B)Uterine cancer
C)Increased cardiovascular problems
D)Vaginal atrophy
سؤال
The goals of therapy when prescribing hormone replacement therapy (HRT) include reducing:

A)Cardiovascular risk
B)Risk of stroke or other thromboembolic event
C)Risk of breast cancer
D)Vasomotor symptoms
سؤال
Why are SERMs generally not ordered for women early into menopause?

A)The rapid onset of severe hot flashes can be unbearable.
B)The bone remodeling effect results in osteoporosis.
C)They tend to induce intermittent spotting.
D)The increased risk of breast cancer isn't worth the benefits of a SERM.
سؤال
Herbals that have proven efficacy for improving vasomotor symptoms include:

A)Black cohosh
B)Red clover
C)Evening primrose
D)None of the above
سؤال
The advantage of vaginal estrogen preparations in the treatment of vulvovaginal atrophy and dryness is:

A)Ability to deliver higher doses of estrogen in a nonoral form
B)The vaginal cream formula provides moisture to the vaginal area.
C)Relief of symptoms without increasing cardiovascular risk
D)All of the above
سؤال
"Menopause" is diagnosed when:

A)The patient has no menses for 12 months.
B)The patient has onset of vasomotor symptoms with irregular menses.
C)The patient has no bleeding cycle for six months.
D)Precise laboratory values are documented.
سؤال
Ongoing monitoring for women on ERT includes:

A)Lipid levels, repeated annually if abnormal
B)Annual health history and review of risk profile
C)Annual mammogram
D)All of the above
فتح الحزمة
قم بالتسجيل لفتح البطاقات في هذه المجموعة!
Unlock Deck
Unlock Deck
1/14
auto play flashcards
العب
simple tutorial
ملء الشاشة (f)
exit full mode
Deck 40: Hormone Replacement Therapy
1
What is the duration of selective estrogen receptor modifier (SERM) use for menopausal issues?

A)It matches the five year duration for estrogen products.
B)The bone health impact allows long-term use.
C)The increased risk of breast cancer encourages tapering as soon as possible.
D)The abnormal lipid profile contributes to an early termination as soon as hot flashes no longer occur.
The bone health impact allows long-term use.
2
Re-evaluation of the Women's Health Study has resulted in what changes in HRT implementation?

A)A combination of estrogen and progestin is no longer required in patients with an intact uterus.
B)Women with breast cancer survivorship over 10 years are no longer considered "at risk."
C)HRT can be used in the first five years of menopause without major risk increase.
D)Low-dose estrogen can be used again in women over 6
HRT can be used in the first five years of menopause without major risk increase.
3
Dosage changes of conjugated equine estrogen (Premarin) are made at _________ intervals.

A)1 to 2 week
B)2 to 4 week
C)6 to 8 week
D)12 week
6 to 8 week
4
Women with an intact uterus should be treated with HRT with both estrogen and progestin due to:

A)Increased risk for endometrial cancer if estrogen alone is used
B)Combination therapy providing the best relief of menopausal vasomotor symptoms
C)Reduced risk for colon cancer with combined therapy
D)Lower risk of developing blood clots with combined therapy
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.
فتح الحزمة
k this deck
5
The optimal maximum time frame for HRT or estrogen replacement therapy (ERT) is:

A)Two years
B)Five years 3.10 years
C)15 years
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.
فتح الحزمة
k this deck
6
Kristine would like to start HRT to treat the significant vasomotor symptoms she is experiencing during menopause. Education for a woman considering HRT includes:

A)Explaining that HRT is totally safe if used short term
B)Telling her to ignore media hype regarding HRT
C)Discussing the advantages and risks of HRT
D)Encouraging her to use phytoestrogens with HRT
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.
فتح الحزمة
k this deck
7
Which of the following is not an indication for starting HRT?

A)Symptomatic hot flashes
B)Treatment or prevention of vaginal atrophy
C)Prevention of osteoporosis
D)Early surgical menopause
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.
فتح الحزمة
k this deck
8
All of the following are risks of exogenous hormones except:

A)Breast cancer
B)Uterine cancer
C)Increased cardiovascular problems
D)Vaginal atrophy
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.
فتح الحزمة
k this deck
9
The goals of therapy when prescribing hormone replacement therapy (HRT) include reducing:

A)Cardiovascular risk
B)Risk of stroke or other thromboembolic event
C)Risk of breast cancer
D)Vasomotor symptoms
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.
فتح الحزمة
k this deck
10
Why are SERMs generally not ordered for women early into menopause?

A)The rapid onset of severe hot flashes can be unbearable.
B)The bone remodeling effect results in osteoporosis.
C)They tend to induce intermittent spotting.
D)The increased risk of breast cancer isn't worth the benefits of a SERM.
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.
فتح الحزمة
k this deck
11
Herbals that have proven efficacy for improving vasomotor symptoms include:

A)Black cohosh
B)Red clover
C)Evening primrose
D)None of the above
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.
فتح الحزمة
k this deck
12
The advantage of vaginal estrogen preparations in the treatment of vulvovaginal atrophy and dryness is:

A)Ability to deliver higher doses of estrogen in a nonoral form
B)The vaginal cream formula provides moisture to the vaginal area.
C)Relief of symptoms without increasing cardiovascular risk
D)All of the above
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.
فتح الحزمة
k this deck
13
"Menopause" is diagnosed when:

A)The patient has no menses for 12 months.
B)The patient has onset of vasomotor symptoms with irregular menses.
C)The patient has no bleeding cycle for six months.
D)Precise laboratory values are documented.
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.
فتح الحزمة
k this deck
14
Ongoing monitoring for women on ERT includes:

A)Lipid levels, repeated annually if abnormal
B)Annual health history and review of risk profile
C)Annual mammogram
D)All of the above
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.
فتح الحزمة
k this deck
locked card icon
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 14 في هذه المجموعة.